<img class="gwt-Image" src="/photo/49846336.cms" /> 
<a href="http://www.businessinsider.in/searchresult.cms?query=Honda">Honda</a> Motorcycle and Scooter India Pvt. Ltd. (HMSI) today launched its final product of the year - the <keyword id="3142530" type="UNKNOWN" weightage="40" keywordseo="125cc-CB-Shine-SP">125cc CB Shine SP</keyword>. 
 The motorcycle comes with a 5 speed gear box, digital analog meter console and <keyword id="20630" type="CITY" weightage="80" keywordseo="Honda">Honda</keyword>’s Eco Technology (HET) and advanced Combi-Brake System (CBS). The new CB Shine SP will be available in 5 colors and three variants and is available at Rs.59,900 for Self-Drum-Alloy, Rs.62,400 for Self-Disc-Alloy and Rs. 64,400 for CBS (Ex-showroom, Delhi). 
 
Speaking at the launch, Mr. <a href="http://www.businessinsider.in/searchresult.cms?query=Keita+Muramatsu">Keita Muramatsu</a>, President &amp; CEO, Honda Motorcycle &amp; Scooter India Pvt. Ltd revealed that the current festive season saw the biggest festive footfalls in India. The company sold over 4.5 lacs unit in Oct 2015, it’s highest ever in a month. 
 
The company saw a 2% jump in the overall market share in the 2 wheelers market. It currently commands a hefty 46% market share in the 125cc motorcycles segment. 125cc infact holds 11.2% of the total 2 wheeler market segment. 
 
When asked about the way forward for Honda, Mr. <a href="http://www.businessinsider.in/searchresult.cms?query=Y.+S.+Guleria">Y. S. Guleria</a>, Senior Vice President – Sales &amp; Marketing, Honda Motorcycle &amp; Scooter India Pvt. Ltd said the majority of the 2 wheelers market in India is focused around the Scooter segment. The company is also running production to its maximum capacity, so new export plans are on hold right now. 
 
India is currently the 2nd largest contributor to Honda’s 300 million user-base worldwide.

Honda vrooms into 125 cc motorcycle segment with new CB
Shine SP

<ul><li><keyword id="8775508" type="COMPANY" weightage="20" keywordseo="remdesivir">Remdesivir</keyword>, steroids, plasma, <keyword id="6284162" type="LOCATION" weightage="20" keywordseo="tocilizumab">Tocilizumab</keyword>, and Favipiravir are some of the most widely used treatments for COVID-19.</li><li>According to <keyword id="40458" type="COMPANY" weightage="20" keywordseo="AIIMS">AIIMS</keyword>’ director Randeep Guleria, the timing of using these drugs — depending on the condition of a COVID-19 patient — is critical in their effectiveness.</li><li>Using them too early or too late could result in harmful side-effects.</li><li>Here are the answers to some of the most frequently asked questions (FAQs) about COVID-19 drugs.</li></ul>(Disclaimer: This should not be considered medical advice. The views and opinions expressed belong to Dr.Randeep Guleria, the director of AIIMS. Please check with your doctor before taking treatment.) It’s been more than a year since the COVID-19 pandemic has been ravaging humanity. Despite predictions that the world would be out of the woods by now, the second wave of the virus is wreaking havoc in countries everywhere, including India. As the number of cases has increased, so has the demand for the drugs that offer potential treatment. This includes everything from the overhyped Remdesivir to less known drugs like Tocilizumab and Favipiravir. These drugs, however, are in short supply. Pharmacies across the country are reporting shortages. Moreover, this has led to a boom in <a href="https://www.businessinsider.in/science/health/news/remdesivir-injection-price-jumps-five-times-as-covid-19-cases-rise/articleshow/82083414.cms">blackmarket sales</a> of these drugs. According to Randeep Guleria, director of All India Institute of Medical Science (AIIMS), these drugs aren’t just something that you can take at home. And the timing of when they should be administered is critical in ensuring that a bad situation isn’t made worse. In a press conference on April 19, Guleria answered some of the most frequently asked questions (FAQs) around COVID-19 and the drugs that fight it. <cmsannotation type="cmsannotation" annotationid="Here’s a quick look at his responses:" comment="subhead" text="Here’s a quick look at his responses:">Here’s a quick look at his responses:</cmsannotation> <ol><li>Is Remdesivir effective in the treatment of COVID-19? No study has conclusively been able to prove that Remdesivir is beneficial in the treatment of COVID-19. “It’s important to understand that Remdesivir is not a magic bullet and it’s not a drug that is reducing mortality,” said Guleria.</li><li>If there is not enough evidence to support the use of Remdesivir to treat COVID 19, why are doctors still prescribing it? “It [Remdesivir] does have a role,” Guleria explained. While everyone has been focused on coming up with a vaccine to fight off the pandemic, the same push has not been seen in the development of antivirals. So, in absence of a good drug that can treat COVID-19, doctors and patients are turning to Remdesivir in hopes of relief.</li><li>When should a patient of COVID 19 take Remdesivir? More important than the drug itself, is the timing of when it is administered. Taking it too early or too late, could do more harm than good.“Remdesivir has been shown to be useful only in those patients who were hospitalised, who showed oxygen saturation and had infiltrates on their chest X-ray or CT scan,” said Guleria. According to him, the optimal timing for Remdesivir is usually after five to seven days of having the virus. “It is of no use if given early to mild or asymptomatic patients,” he told the press. “It is of no use if it’s given very late because it would create a cytokine storm.” A cytokine storm is when the immune system goes into overdrive. The body starts to attack its own cells and tissues instead of just the virus.</li><li>Is Remdesivir something you can take at home? Remdesivir isn’t just a pill that you can down with a glass of water. It comes in a vial and has to be injected into the body. So, ideally, one should not be taking it at home.“It is for patients who are hospitalised and severe. Therefore it should not be given at home. It is for patients who need to be admitted and need hospital care,” said Guleria. </li><li>Are steroids effective in the treatment of COVID 19? Unlike Remdesivir, there is evidence to support the use of steroids in the treatment of COVID-19. The <keyword id="6356311" type="COMPANY" weightage="20" keywordseo="World-Health-Organisation">World Health Organisation</keyword>’s (WHO) recovery trial showed that steroids do have a beneficial effect. “But again, the timing is critical. The recovery trial clearly showed that if we give steroids too early, before oxygen saturation, it showed a harmful effect. Those who got it early had higher mortality than those who did not,” warned Guleria.According to him, steroids are most effective during the later part of the disease, when there is more inflammation and oxygen saturation is falling. “Steroids are only useful for moderate or severe cases,” he said.</li><li>Is plasma a good way to fight off COVID-19? Plasma was popular when COVID-19 initially came around but studies in India, and around the world, have determined that it is not effective in the treatment. “Subsequently, other studies have been done and a large meta analysis as well which combines results of all the studies, have shown that plasma is not effective in treating COVID-19,” said Guleria.</li><li>Should a person with COVID-19 take Tocilizumab? Tocilizumab is a drug of last resort. According to Guleria, it should only be used when a COVID-19 infection in a patient is worsening despite steroids, Remdesivir, and other treatments like anticoagulants. “Tocilizumab is required in less than 2% of COVID 19 patients. Very few patients need this drug because it's only for treating a cytokine storm… And, therefore, it has a limited role,” he explained.</li><li>Is Favipiravir effective in treating COVID-19? Favipiravir is another antiviral that is being promoted for the treatment of COVID 19. It was initially doled out as a treatment of influenza after the H1N1 pandemic.“There is not enough evidence in robust studies to show that it is a good drug. In most countries, it is not being used. They’re not finding higher mortality,” said Guleria. And, since it’s not a proven treatment, India’s national guidelines also don’t recommend its use. </li><li>Is it possible to treat COVID-19 without any of the drugs mentioned above? According to Guleria, people with mild COVID-19 or those who are asymptomatic will improve with just symptomatic treatment.“Outside [in other countries] they treat COVID-19 with paracetamol, good hydration and multivitamins — all of them have recovered without any treatment,” he told reporters. “Giving treatment when it is not required, you may be doing more harm than good.”</li></ol>SEE ALSO: <a href="https://www.businessinsider.in/careers/news/for-saas-y-salaries-indian-engineers-are-skipping-the-traditional-it-services-queue/articleshow/82157280.cms">SaaS-y salaries are 30% more than traditional IT services — and they’re making it tougher for traditional IT service firms to find the right talent</a> <a href="https://www.businessinsider.in/business/startups/news/tiger-global-invests-in-healthcare-startup-pristyn-care-valuation-more-than-doubles-in-six-months/articleshow/82158467.cms">Tiger Global invests in healthcare startup Pristyn Care, valuation more than doubles in six months</a> <a href="https://www.businessinsider.in/india/news/india-has-the-142nd-rank-of-the-180-countries-in-the-world-press-freedom-index-falls-behind-myanmar-sri-lanka-and-nepal/articleshow/82158331.cms">India still has the ‘bad’ classification in the World Press Freedom Index, falls behind Myanmar, Sri Lanka and Nepal</a>

When to use Remdesivir, Favipiravir, Steroids and Tocilizumab drugs for covid 19 treatment: AIIMS doctor explains

<img class="gwt-Image" src="/photo/42697140.cms" />NEW DELHI: India has become the biggest two-wheeler market in the world for Japanese major <keyword id="20630" type="CITY" weightage="80" keywordseo="Honda">Honda</keyword>, nearly three years after it decided to go solo following the split with Munjals of Hero. 
 
Sales in India have emerged as the highest for Honda across its global operations, led by a strong demand for its scooters and a slow-but-gradual pick-up in motorcycle volumes. 
 Honda's fully-owned Indian subsidiary, <keyword id="153241" type="COMPANY" weightage="80" keywordseo="Honda-Motorcycles">Honda Motorcycles</keyword> and <keyword id="149019" type="COMPANY" weightage="80" keywordseo="Scooter-India">Scooter India</keyword> (<keyword id="121221" type="ORGANIZATION" weightage="100" keywordseo="HMSI">HMSI</keyword>), emerged as the top-seller for the company in July, and followed the feat in August. The leadership assumes significance considering HMSI was at the fourth place in Honda's twowheeler pecking order just three years back with top three ranks being occupied by <keyword id="8692" type="COUNTRY" weightage="80" keywordseo="Indonesia">Indonesia</keyword>, <keyword id="13486" type="COUNTRY" weightage="80" keywordseo="Vietnam">Vietnam</keyword> and <keyword id="3739" type="COUNTRY" weightage="80" keywordseo="Thailand">Thailand</keyword>. 
 
"The high demand in India has helped us achieve an aggressive growth rate, which has taken us to the top position in Honda's two-wheeler business," Keita Muramatsu, president &amp; CEO of HMSI, told TOI. 
 
Indonesia had been the top market for Honda in two-wheelers till India displaced it in July. 
 
HMSI - the second-biggest two-wheeler maker in India behind Hero MotoCorp - sold 3.8 lakh units in July (up 33% y-oy) and 3.9 lakh units in August (26% up y-o-y). 
 
HMSI's strong run will mean the company will contribute 25% of Honda's global two-wheeler sales this fiscal against 22% in the previous fiscal. HMSI expects to sell 45 lakh units this fiscal against 37 lakh units it sold in 2013-14. 
 Muramatsu said strong performance of scooters, especially the 'Activa' model, has played a key part in fuelling the company's growth. Scooter sales have been the backbone of HMSI's operations in India and have single-handedly worked at reviving the dying segment after the exit of <keyword id="6358511" type="COMPANY" weightage="100" keywordseo="Bajaj">Bajaj</keyword> Auto. 
 
"Changing lifestyles, rising number of female riders and increased demand from semi-urban regions have led the growth in scooter sales," Muramatsu said. 
 
Y S Guleria, VP (sales &amp; marketing) of HMSI, said the company is now boosting vehicle production as well as presence in the market as it plans at least one new model every quarter. "We have an annual production capacity of around 4.6 million units. The new factory in Gujarat, which should be operational by the first quarter of 2016, will add an additional 1.2 million units to our capacity." The company, which has invested around Rs 6,200 crore, is rapidly expanding its presence in India and getting deeper into smaller towns and rural areas. 
 
Image: Zigwheels

India Largest 2-Wheeler Market For Honda In The World

<img class="gwt-Image" src="/photo/44846304.cms" />This is good news for the <keyword id="6356076" type="UNKNOWN" weightage="80" keywordseo="indian-economy">Indian economy</keyword>, which will surely get a boost from high-end bikes and scooters production within India. <keyword id="20630" type="CITY" weightage="80" keywordseo="Honda">Honda</keyword> Motorcycles and <keyword id="173465" type="CITY" weightage="80" keywordseo="Scooters-India">Scooters India</keyword> (<keyword id="121221" type="ORGANIZATION" weightage="80" keywordseo="HMSI">HMSI</keyword>) announced yesterday that they are setting up Rs 1,100 Crore manufacturing plant in Gujarat, which will majorly be responsible to produce scooters. With this HMSI will also start producing top of the line motorbikes in India starting with the CBR 650 sports bike. 
 The production of these motor bikes should start in 2015. "We announce that (from) next year Honda will start making CBR -650 in India. By this, we will not only open up the skill of our existing manpower but it will also showcase the <keyword id="109276" type="COMPANY" weightage="80" keywordseo="Honda-India">Honda India</keyword>'s manufacturing quality to the world," Said HMSI Vice-President Y S Guleria. 
 However, it is still unclear that the same Gujarat plant will start producing the high-end bikes as well. Honda might be looking for another place to setup shop to for superbike production in India. This means that they will <keyword id="47916" type="UNKNOWN" weightage="80" keywordseo="invest">invest</keyword> more money in the country, which will churn more job opportunities. 
 
HMSI already has plants in Rajasthan, Haryana and Karnataka and with the Gujarat plant coming to effect in 2015 they will have a greater hold in the two wheeler market. 
 
It is said that the new plant in Gujarat will have over 3,000 employees and will be the largest scooter manufacturing unit in the world. For a country like India where scooters are a common mode of transportation, this is very good news. As Honda can now probably give its scooter offerings at a very attractive rates to its customers.

Honda Will Produce High-End Sports Bikes In India And Be
Part Of Modi’s Make In India Campaign

<img class="gwt-Image" src="/photo/42534610.cms" />
 <keyword id="109276" type="COMPANY" weightage="20" keywordseo="Honda-India">Honda India</keyword>’s two wheeler arm, Honda Motorcycle &amp; Scooter India Pvt Ltd (HMSI) has signed a Memorandum of Understanding (MoU) with state-run <keyword id="62034" type="CITY" weightage="20" keywordseo="Punjab-National-Bank">Punjab National Bank</keyword> to provide <keyword id="6354851" type="ORGANIZATION" weightage="20" keywordseo="Retail">retail</keyword> finance to Honda two wheeler buyers. 
	 
	“This alliance is first of its kind in the two-wheeler industry - both for Honda and PNB. Propelled by this partnership with Punjab National Bank, we aim to grow Honda's retail finance significantly in coming months,” said Y S Guleria, Vice President, Sales and Marketing, HMSI. 
	Through this strategic alliance, company aims to tap its target audience in rural areas. “With 40% of branches of PNB in rural areas and additional 24% in semi-urban areas, Honda's strategic alliance with Punjab National Bank will help it make deeper inroads into hinterland”, the company said in a statement. 
	 
	By availing this offer, customers can save up to Rs 10,000 by getting loan finance for 90% of the value of the product at a lower rate of interest of 12.25%. The auto maker claims that the interest rate is the lowest in the industry. 
	 
	Commenting on the partnership, S S Bhatia, General Manager, Retail Assets Division, Punjab National Bank said that the bank has offered two retail finance schemes through this alliance. “Our Bank has 80 specialized retail asset branches at prime locations for financing only retail loans. Honda is synonymous globally with high quality products at reasonable prices…Through customized and convenient finance options, we look forward to partnering Honda in fulfilling the dreams and aspirations of millions in India,” added Bhatia. 
	 
	Reports suggest that HMSI is expecting to clock in a sale of 4.5 million scooters and motorcycles in the current fiscal year, posting a growth of 22% against 3.7 million units sold in the last fiscal year.

You Searched For "Y S Guleria" and got 5 results

Honda vrooms into 125 cc motorcycle segment with new CB Shine SP

BI India Bureau

When to use Remdesivir, Favipiravir, Steroids and Tocilizumab drugs for covid 19 treatment: AIIMS doctor explains

BI India Bureau

India Largest 2-Wheeler Market For Honda In The World

Times Of India

Honda Will Produce High-End Sports Bikes In India And Be Part Of Modi’s Make In India Campaign

Sulabh Puri

Honda India To Woo Customers Through Easy Retail Loans; Ties-Up With PNB

Purba Das